Skip to main content
Sam-A Pharm. Co. Ltd logo

Sam-A Pharm. Co. Ltd — Investor Relations & Filings

Ticker · 009300 ISIN · KR7009300005 KO Manufacturing
Open in API
Filings indexed 105 across all filing types
Latest filing 2021-03-19 Audit Report / Informat…
Country KR South Korea
Listing KO 009300

About Sam-A Pharm. Co. Ltd

https://www.samapharm.co.kr/eng/main201…

Sam-A Pharm. Co. Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of a range of pharmaceutical products. The company specializes in several therapeutic areas, with a primary focus on treatments for respiratory and dermatological conditions. Its portfolio also includes antipyretic, analgesic, and anti-inflammatory medications. Founded in 1945, Sam-A Pharm. operates manufacturing facilities that adhere to high-quality production standards, equivalent to EU-GMP, reflecting its long-standing commitment to improving health and quality of life.

Recent filings

Filing Released Lang Actions
[기재정정]감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korean DART system (indicated by the structure and terminology like '감사보고서 제출' and '정정신고'). It provides the audit results, financial highlights, and auditor information for Sam-A Pharmaceutical. While it contains financial data, it is a formal regulatory disclosure of the audit report rather than the full annual report (10-K) or a simple announcement (RPA). Given the specific nature of audit report filings in the Korean regulatory context, it falls under the Audit Report category. FY 2020
2021-03-19 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its AGM on a date that coincides with many other companies, citing internal audit and reporting schedules. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a voting result, it falls under the general regulatory filing category.
2021-03-15 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Sam-A Pharmaceutical. It contains the agenda for the 48th Annual General Meeting, including the approval of financial statements, director remuneration, and audit reports. It also includes management's discussion and analysis (business overview, market status) and preliminary financial statements (balance sheet, income statement, cash flow). This type of document is a standard proxy statement/information circular provided to shareholders ahead of an AGM to solicit votes and provide necessary information for the meeting.
2021-03-15 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Sam-A Pharmaceutical. It outlines the date, location, and agenda items (financial statements, dividend approval, and director compensation). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2021-03-10 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Sam-A Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2021-02-25 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Sama Pharmaceutical) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (KRX) for listed companies to report preliminary financial results or material changes before the final audit is completed. Since it provides key financial highlights and performance metrics rather than a full annual report or a simple announcement of a report's availability, it falls under the Earnings Release (ER) category. FY 2020
2021-02-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.